Initial notification · 09.09.2026
Supply shortage Germany: Dexa-inject mibe 10 mg/ml
Affected country: Germany · Reported period: 02.09.2026 – 29.01.2027 · Active ingredient: Dexamethasondihydrogenphosphat-Dinatrium (Ph.Eur.)
Notice context
A supply shortage has been recorded for Dexa-inject mibe 10 mg/ml in Germany. The stated reason is “Other”. The notice concerns the active ingredient Dexamethasondihydrogenphosphat-Dinatrium (Ph.Eur.) and is identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Germany. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Dexa-inject mibe 10 mg/ml is a supply signal concerning Dexamethasondihydrogenphosphat-Dinatrium (Ph.Eur.) in Germany. The published reason “Other” determines which data should be verified first.
Because the published reason does not establish a reliable operational cause, availability, source, timing, product status and the supply route should be verified without adding an unsupported explanation.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess source, product status, timing, lawful sourcing route and any buffer stock without adding an unsupported cause.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
A resilient stock concept for Dexa-inject mibe 10 mg/ml requires prior verification of product status, demand, coverage and the permitted supply route.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using PZN 19847325, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 02.09.2026 to 29.01.2027 with the primary source and potential suppliers.
- Prioritise hospital demand, supply relevance and the escalation route with the accountable market participants.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Dexa-inject mibe 10 mg/ml: